REG - Aptamer Group PLC - Block listing Interim Review

AptamerAnnouncement

28/02/2023 18:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230228:nRSb4049Ra&default-theme=true

RNS Number : 4049R  Aptamer Group PLC  28 February 2023

28 February 2023

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

 

Block Listing Interim Review

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
enable innovation in the life sciences industry, makes the following
notification pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for
Companies regarding its existing block admission:

 

 

 Name of Company                                                                 Aptamer Group plc
 Name of Scheme                                                                  The Aptamer Group EMI Share Option Scheme
 Period of Return (from/to)                                                      25 August 2022 to 24 February 2023
 Number and class of securities not issued at the start of the period under the  1,792,400 Ordinary Shares
 scheme
 Number of securities issued under the scheme during the period                  34,123
 Options waived and not to be exercised                                          91,800
 Balance under the scheme of securities not yet issued at the end of the period  1,666,477
 Number and class of securities originally admitted and the date of admission    2,063,200 Ordinary Shares on 25 February 2022
 Name of contact and telephone number                                            Jenny Cutler +44 (0) 1904 217 404

 

 

 

 

- ENDS -

 

For further information, please contact:

 

 

 Aptamer Group plc                                                  +44 (0) 1904 217 404
 Dr Arron Tolley - CEO

 SPARK Advisory Partners Limited - Nominated Adviser                +44 (0) 20 3368 3550
 Andrew Emmott / Mark Brady / Adam Dawes

 Liberum Capital Limited - Broker                                   +44 (0) 20 3100 2000
 Richard Lindley / Ben Cryer / Cara Murphy

 Consilium Strategic Communications                                 +44 (0) 20 3709 5700
 Matthew Neal / Chris Welsh / Lucy Featherstone

 

aptamergroup@consilium-comms.com (mailto:aptamergroup@consilium-comms.com)

 

About Aptamer Group plc

 

Aptamer (http://www.aptamergroup.com/)  Group develops custom affinity
binders through its proprietary Optimer(®) platform to enable new approaches
in therapeutics, diagnostics and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer
platform.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global antibody market is currently worth over
$145bn. Optimer binders are engineered to address many of the issues found
with alternative affinity molecules, such as antibodies, and offer new,
innovative solutions to bioprocessing, diagnostic and pharmaceutical
scientists.

Aptamer Group has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and processes, scientists and
collaborators are enabled to make faster, more informed decisions that support
discovery and development across the Life Sciences.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRDVLFLXLLZBBZ